[A23-18] Esketamine (treatment-resistant major depressive disorder) – Benefit assessment according to §35a Social Code Book V
Last updated 21.09.2023
Project no.:
A23-18
Commission:
Commission awarded on 16.03.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Mental and emotional wellbeing
Adults with treatment-resistant major depressive disorder, who have not responded to at least 2 different treatments with antidepressants in the current moderate to severe depressive episode
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A23-75 | Esketamine (treatment-resistant major depressive disorder) – Addendum to Commission A23-18 | Commission completed |
Federal Joint Committee (G-BA)
2023-09-21 A G-BA decision was published.